Genetic Markers For Breast And Ovarian Cancer
Tech ID: 18310 / UC Case 1994-041-0
Specific BRCA1 mutations, PCR primers and hybridization probes are used in nucleic acid-based methods for diagnosis of inheritable breast cancer susceptibility. Additionally, binding agents, such as antibodies, specific for peptides encoded by the subject BRCA1 mutants are used to identify expression products of diagnostic mutations/rare alleles in patient derived fluid or tissue samples. Compositions with high binding affinity for transcription or translation products of the disclosed BRCA1 mutations and alleles are of potential use in therapeutic intervention. Such products include anti-sense nucleic acids, peptides encoded by the subject nucleic acids, and binding agents such as antibodies, specific for such peptides.
DNA sequence identification of BRCA1 mutants and methods for identifying patients with such mutations.
Methods for the identification of polypeptides produced from BRCA1 mutant genes.
Breast cancer screening based on genetic propensity
|United States Of America||Issued Patent||6,512,091||01/28/2003||1994-041|
|United States Of America||Issued Patent||5,821,328||10/13/1998||1994-041|
|United States Of America||Issued Patent||5,622,829||04/22/1997||1994-041|
Additional Patent Pending
marker, diagnostic, detection, assay, biochip, diagnostic tool, microarrays, therapeutic
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- Diagnostic Test for Cancer Susceptibility
- Hybridomas Producing Monoclonals Against Listeria Monocytogenes Antigens And Cloned Genes For The Antigen Proteins.
- Hybridoma 2f1, Producing Monoclonal Antibody Specific For Mouse Klrg1
- Hybridoma 16a11, Producing Monoclonal Antibody Specific For Mouse Nkg2a
- Monoclonal Antibodies Against Non-muscle Myosin Ii